NCT03161093: A reported trial by Regeneron Pharmaceuticals
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT03161093 |
|---|---|
| Title | A Phase 3 Randomized, Double-blind, Multi-dose, Placebo and Naproxen-Controlled Study to Evaluate the Efficacy and Safety of Fasinumab in Patients With Pain Due to Osteoarthritis of the Knee or Hip |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Aug. 17, 2017 |
| Completion date | Sept. 9, 2019 |
| Required reporting date | Sept. 9, 2022, midnight |
| Actual reporting date | Aug. 25, 2022 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |